Novel and Emerging Oral GLP-1 RAs: Advancing Personalized Care for Canadians With Type 2 Diabetes
Please visit answersincme.com/BHT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara Stafford, MDCM, FRCPC and Gihane Zarifa, MD, CCFP, FCFP, MSc. In this activity, experts in family medicine and endocrinology discuss the role of oral glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in personalized type 2 diabetes (T2D) management. Upon completion of this activity, participants should be better able to: Discuss individualized, guideline-informed management strategies for T2D that address glycemic control, weight, and patient-specific factors; Differentiate key pharmacologic, administration, and tolerability characteristics of oral GLP-1 RAs to support patient counseling in T2D; and Interpret clinical evidence for approved and emerging oral GLP-1 RAs to inform their potential role in addressing gaps in T2D management.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from CME in Minutes: Education in Primary Care
Targeting TROP2 in Oncology: Pan-Tumor Insights and the Next Wave of ADC Innovation
Optimizing Real-World Management of Early Alzheimer’s Disease: Maintenance Therapy and Long-Term Evidence
Case-Based Guidance on Tailoring Treatment Selection for Menopause-Related VMS
Sniffing Out Better Chronic Rhinosinusitis With Nasal Polyps Outcomes: Targeting Smell, Sleep, and Comorbidities With Biologics
Get summaries like this every morning.
Free AI-powered recaps of CME in Minutes: Education in Primary Care and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.